Yamile Calle-López

Dr. Yamile Calle-López

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2020 in Epilepsia
Verified
Journal Article
Open access
PDF file
ASArthur Stefanski
Arthur Stefanski
YCYamile Calle-López
Yamile Calle-López
CLCostin Leu
Costin Leu
EPEduardo Pérez‐Palma
Eduardo Pérez‐Palma
EPElia Pestana‐Knight
Elia Pestana‐Knight
DLDennis Lal
Dennis Lal
Objective: Clinical genetic sequencing is frequently utilized to diagnose individuals with neurodevelopmental disorders (NDDs). Here we perform a meta‐analysis and systematic review of the success rate (diagnostic yield) of clinical sequencing through next‐generation sequencing (NGS) across NDDs. We compare the genetic testing yield across NDD subtypes and sequencing technology.Methods: We performed a systematic review of the PubMed literature until May 2020. We included clinical sequencing studies that utilized NGS in individuals with epilepsy, autism spectrum disorder (ASD), or intellectual disability (ID). Data were extracted, reviewed, and categorized according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Two investigators performed clinical evaluation and grouping following the International League Against Epilepsy (ILAE) guidelines. Pooled rates of the diagnostic yield and 95% confidence intervals were estimated with a random‐effects model.Results: We identified 103 studies (epilepsy, N = 72; ASD, N = 14; ID, N = 21) across 32,331 individuals. Targeted gene panel sequencing was used in 73, and exome sequencing in 36 cohorts. Given highly selected patient cohorts, the diagnostic yield was 17.1% for ASD, 24% for epilepsy, and 28.2% for ID (23.7% overall). The highest diagnostic yield for epilepsy subtypes was observed in individuals with ID (27.9%) and early onset seizures (36.8%). The diagnostic yield for exome sequencing was higher than for panel sequencing, even though not statistically significant (27.2% vs 22.6%, P = .071). We observed that clinical sequencing studies are performed predominantly in countries with a high Inequality‐adjusted Human Development Index (IHDI) (countries with sequencing studies: IHDI median = 0.84, interquartile range [IQR] = 0.09 vs countries without sequencing studies: IHDI median = 0.56, IQR = 0.3). No studies from Africa, India, or Latin America were identified, indicating potential barriers to genetic testing.Significance: This meta‐analysis and systematic review provides a comprehensive overview of clinical sequencing studies of NDDs and will help guide policymaking and steer decision‐making in patient management.

1 July 2019 in Epilepsia
Verified
Journal Article
Closed access
PDF file
YCYamile Calle-López
Yamile Calle-López
LLLady Diana Ladino
Lady Diana Ladino
VBVanessa Benjumea‐Cuartas
Vanessa Benjumea‐Cuartas
DCDiana Marcela Castrillón‐Velilla
Diana Marcela Castrillón‐Velilla
JTJosé Francisco Téllez‐Zenteno
José Francisco Téllez‐Zenteno
PWPeter Wolf
Peter Wolf

1 April 2021 in Epilepsy & Behavior
Verified
Journal Article
Closed access
AAAli Asadi-Pooya
Ali Asadi-Pooya
FBFrancesco Brigo
Francesco Brigo
SLSimona Lattanzi
Simona Lattanzi
IKIoannis Karakis
Ioannis Karakis
MAMarjan Asadollahi
Marjan Asadollahi
AJAsel Jusupova
Asel Jusupova


1 February 2021 in Epilepsy & Behavior
Verified
Journal Article
Closed access
AAAli Asadi-Pooya
Ali Asadi-Pooya
Francesco BrigoFrancesco Brigo
Francesco Brigo
SLSimona Lattanzi
Simona Lattanzi
LDLuciana D'ALessio
Luciana D'ALessio
ADAnilu Daza-Restrepo
Anilu Daza-Restrepo
MLMaria E. Lozada
Maria E. Lozada

1 October 2019 in Epileptic Disorders
Verified
Journal Article
Closed access
YCYamile Calle-López
Yamile Calle-López
PKPrakash Kotagal
Prakash Kotagal
EKElia Pestana Knight
Elia Pestana Knight
Antiepileptic drug side effects are frequent, 42% of them corresponding to cosmetic changes. The most frequent effects are weight gain, gingival hyperplasia, and hair loss. Hair changes in texture or colour are rarely reported in the literature. We present a case of hair curling after the introduction of perampanel. A 13‐year‐old girl with genetically confirmed Pitt‐Hopkins syndrome with uncontrolled seizures, while on treatment with levetiracetam and valproic acid, was started on perampanel, reaching seizure control. After a few weeks of the introduction of the new antiepileptic drug, she developed hair curling. Hair curling is a rare cosmetic side effect, reported mainly in patients under valproic acid treatment. Perampanel is a recently introduced pharmaceutical molecule with no prior reports of hair changes as a side effect. There is no clear explanation for this side effect, but it should be discussed with patients taking valproate whenever perampanel is added to the treatment.